Akero aims to develop and deliver transformational medicines to patients with high unmet medical need. Akeroâs current focus is advancing our lead program, AKR-001, to provide a powerful new therapy for patients with NASH (non-alcoholic steatohepatitis). Akero is led by industry veterans with decades of experience delivering innovative medicines to patients. We are united in our commitment to developing transformational new therapies for NASH and other serious metabolic diseases. Source
No articles found.
Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...
Stoke is pioneering a new way to treat the unde...
Vanda is developing important new medicines to improve the lives of patients. We u...
Vanda is developing important new medicines to ...
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, an...
Shionogi & Co., Ltd. engages in the research, d...
Cortexyme is a biopharmaceutical company developing therapeutics based on data sup...
Cortexyme is a biopharmaceutical company develo...
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the ...
AcelRx Pharmaceuticals, Inc. is a specialty pha...
Smart Rx Systems has created a medication management system that dispenses medicat...
Smart Rx Systems has created a medication manag...
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...
GENFIT is a late-stage biopharmaceutical compan...
Join the National Investor Network and get the latest information with your interests in mind.